Isthmus Partners LLC Has $4.92 Million Stock Holdings in iRadimed Corporation $IRMD

Isthmus Partners LLC reduced its position in iRadimed Corporation (NASDAQ:IRMD) by 13.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 50,611 shares of the medical equipment provider’s stock after selling 8,129 shares during the period. Isthmus Partners LLC’s holdings in iRadimed were worth $4,923,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Royal Bank of Canada increased its position in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of iRadimed by 7.5% in the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after buying an additional 1,108 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares during the last quarter. Institutional investors own 92.34% of the company’s stock.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $101.38, for a total transaction of $506,900.00. Following the transaction, the chief executive officer directly owned 2,242,500 shares of the company’s stock, valued at approximately $227,344,650. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 60,000 shares of company stock valued at $5,661,603 in the last 90 days. Corporate insiders own 36.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IRMD shares. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings upgraded shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Trading Down 0.5%

Shares of NASDAQ IRMD opened at $86.44 on Friday. The firm has a market cap of $1.10 billion, a P/E ratio of 47.24 and a beta of 0.90. iRadimed Corporation has a 1-year low of $50.88 and a 1-year high of $107.90. The business’s 50 day moving average is $93.68 and its 200-day moving average is $94.67.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Analysts forecast that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a $0.20 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is 43.72%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.